GlassScriptPhysician profile
Russell Patrick Jackson
NPI 1699322578
$1,547.22
in general payments reported to CMS, 2019-2025
30 companies · $836 in 2025
The $836 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.11 · 2022: $316 · 2023: $195 · 2024: $175 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.77 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $214.83 | 2022-2025 | |
| Amgen INC. | $201.68 | 2024-2025 | Otezla, Repatha, Krystexxa |
| Novo Nordisk INC | $125.65 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $100.02 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $91.47 | 2025 | Gemtesa, Myfembree |
| Pfizer INC. | $91.10 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.54 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $83.80 | 2022-2025 | Zepbound |
| Lucid Diagnostics INC. | $65.02 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.89 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $39.93 | 2023 | |
| Hikma Pharmaceuticals USA | $36.95 | 2022 | |
| Abbott Laboratories | $30.52 | 2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $26.54 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.11 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $24.56 | 2023 | Aptima |
| Astellas Pharma US INC | $24.34 | 2025 | Veozah |
| Recordati_rare_diseases_inc. | $23.06 | 2025 | Isturisa |
| Boston Scientific Corporation | $22.53 | 2022 | |
| Tonix Medicines, INC. | $21.11 | 2025 | Tonmya |
| Oxford Immunotec USA INC | $20.72 | 2022 | |
| Exact Sciences Corporation | $19.95 | 2025 | Cologuard Collection Kit |
| Ascensia Diabetes Care US INC. | $18.90 | 2025 | |
| Merck Sharp & Dohme LLC | $18.66 | 2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $17.40 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $16.75 | 2025 | Rexulti |
| Lundbeck LLC | $15.84 | 2025 | Rexulti |
| Corcept Therapeutics | $14.54 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $13.30 | 2023 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $7.51 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.